Retirement of Tony Hunt

After more than a decade at the helm, Tony Hunt will step down as Executive Chair while still remaining with the company as an advisor until March 2027. Olivier Loeillot, President and CEO of Repligen, expressed gratitude for Hunt's extensive service, highlighting his role in expanding the company's diverse portfolio of innovative products. "Tony has left a strong foundation for us to build upon," said Loeillot.

Incoming Chair Dr. Martin D. Madaus

Dr. Martin D. Madaus, a director at Repligen since February 2023, brings over 36 years of industry experience to his new role. Previously, he served as Chairman, President, and CEO of Millipore Corporation, where he played a key role in its transformation and subsequent acquisition by Merck KGaA in 2010. Dr. Madaus holds a D.V.M. from the University of Munich and a Ph.D. from the University of Veterinary Medicine of Hanover.

In expressing his gratitude for the board's support, Dr. Madaus stated, "I am honored to be elected as Chair of the Repligen Board and look forward to guiding Repligen towards new heights.”

Implications for Repligen's Future

Hunt's departure marks a pivotal moment for RGEN as the company looks to maintain its trajectory of growth. He reflected on his tenure by saying, “I leave this Company immensely proud of the business we have created together... I am confident that Olivier and Martin will build on the success we have enjoyed and lead Repligen to a new phase of growth.”

About Repligen Corporation

Repligen Corporation is a global leader in developing innovative bioprocessing technologies that enhance the efficiency of biological drug manufacturing. The company’s key focus areas include:

• Filtration and Fluid Management
• Chromatography
• Process Analytics
• Proteins

Headquartered in Waltham, Massachusetts, Repligen has manufacturing facilities across the U.S. and in countries such as Estonia, France, Germany, Ireland, the Netherlands, and Sweden. For more information about RGEN, visit their website at www.repligen.com or follow them on LinkedIn.

Forward-Looking Statements

This announcement may include forward-looking statements concerning Repligen Corporation. Investors are advised that actual results may vary significantly from those anticipated, due to various risks and uncertainties detailed in the company’s filings with the Securities and Exchange Commission.

Contact Information

For further information, please contact:

Jacob Johnson
VP, Investor Relations
781-419-0204
investors@repligen.com